Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/22527
Title: Parathyroid hormone receptor 1 (PTHR1) is a prognostic indicator in canine osteosarcoma.
Authors: Al-Khan, Awf A;Nimmo, Judith S;Tayebi, Mourad;Ryan, Stewart D;Simcock, James O;Tarzi, Raboola;Kuntz, Charles A;Saad, Eman S;Day, Michael J;Richardson, Samantha J;Danks, Janine A
Affiliation: Murdoch University, School of Veterinary and Life Sciences, Murdoch, 6150, Australia
Western Sydney University, School of Medicine, Campbelltown, 2560, Australia
Australian Specialised Animal Pathology Laboratory, Mulgrave, 3170, Australia
Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
RMIT University, School of Science, Bundoora, 3083, Australia
RMIT University, School of Health and Biomedical Sciences, Bundoora, 3083, Australia
Suhar Hospital, Department of Pathology, Suhar, 311, Oman..
Southpaws Veterinary Hospital, Department of Surgery, Moorabbin, 3189, Australia
The University of Melbourne, Faculty of Veterinary & Agricultural Sciences, Translational Research and Animal Clinical Trial Study Group (TRACTS), Werribee, 3030, Australia
Issue Date: 31-Jan-2020
EDate: 2020-01-31
Citation: Scientific reports 2020; 10(1): 1564
Abstract: Osteosarcoma (OS) is the most common malignant primary bone tumour in humans and dogs. Several studies have established the vital role of parathyroid hormone-related protein (PTHrP) and its receptor (PTHR1) in bone formation and remodeling. In addition, these molecules play a role in the progression and metastasis of many human tumour types. This study investigated the expression of PTHR1 and PTHrP in canine OS tissues and assessed their prognostic value. Formalin-fixed, paraffin-embedded tissue samples from 50 dogs diagnosed with primary OS were immunolabeled with antibodies specific for PTHR1 and PTHrP. The immunostaining intensity of tumours from patients with OS was correlated with survival time. Both PTHR1 and PTHrP were detected in all OS samples (n = 50). Dogs with OS tumours showing high immunostaining intensity for PTHR1 (n = 36) had significantly shorter survival times (p = 0.028, Log Rank; p = 0.04, Cox regression) when compared with OS that had low immunostaining intensity for PTHR1 (n = 14).PTHrP immunostaining intensity did not correlate with survival time (p > 0.05). The results of this study indicate that increased expression of PTHR1 antigen in canine OS is associated with poor prognosis. This suggests that PTHR1 may be useful as a prognostic indicator in canine OS.
URI: http://ahro.austin.org.au/austinjspui/handle/1/22527
DOI: 10.1038/s41598-020-58524-3
ORCID: 0000-0001-8664-6918
0000-0001-7016-771X
0000-0002-2789-3449
PubMed URL: 32005896
Type: Journal Article
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.